WO1993011757A1 - Drug formulations for parenteral use - Google Patents
Drug formulations for parenteral use Download PDFInfo
- Publication number
- WO1993011757A1 WO1993011757A1 PCT/FI1992/000339 FI9200339W WO9311757A1 WO 1993011757 A1 WO1993011757 A1 WO 1993011757A1 FI 9200339 W FI9200339 W FI 9200339W WO 9311757 A1 WO9311757 A1 WO 9311757A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- toremifene
- drug
- cyclodextrin
- hydroxypropyl
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- This invention relates to drug formulations of antiestrogens, ⁇ particularly antiestrogens comprising a triphenylbutene moiety, for use in parenteral administration.
- Toremifene, desmethyl toremifene, desmethyl tamoxifen and tamoxifen are all examples of substituted triphenylbutenes useful in cancer therapy.
- toremifene CH3 Cl desmethyl toremifene H Cl tamoxifen CH3 H desmethyl tamoxifen H H
- toremifene may well be used together with other anticancer drugs to enhance their efficacy
- parenteral drug formulations according to this invention include emulsions, aqueous solutions of cyclodextrin - drug complexes and liposomes.
- Cyclodextrins are all cyclic oligomers of glucose.
- the cyclodextrins can form inclusion complexes with drugs in that the drug molecule is included in the lipophile-seeking cavities of the cyclodextrin molecule. Therefore the cyclodextrins effectively solubilize lipophilic drugs into aqueous media.
- the use of cyclodextrins in the pharmaceutical field has been described e.g. in Drug Development and Industrial Pharmacy, 17(11), 1503-1549, 1991.
- One object of this invention is a parenteral formulation based on a 2-hydroxypropyl cyclodextrin, preferably 2-hydroxypropyl ⁇ -cyclodextrin or 2-hydroxypropyl-r- cyclodextrin, complex including an active drug substance selected from the group consisting of toremifene, desmethyltoremifene, tamoxifen and desmethyltamoxifen or a pharmaceutically acceptable non-toxic salt thereof, said complex being present in an aqueous solution.
- Emulsions of the antiestrogens mentioned above can be made by dispersing the drug or a cylodextrin complex of said drug into a pharmaceutically acceptable emulsifier, and optionally adding a stabilizing agent.
- Liposomes are spherical particles in an aqueous medium, formed by a lipid bilayer enclosing an aqueous compartment.
- the lipid surface may be either unilamellar or multilamellar.
- the liposomes may be loaded with either hydrophobic or hydrophilic drug substances.
- Another object of the invention is a parenteral formulation based on the drug substance as such loaded into liposomes .
- DMPG diristoylphosphatidylglycerol
- POPC l-palmitoyl-2-oleoyl-sn-glycero-3-phosphorylcholine
- liposomes can be made directly by dissolving the drug or the drug-cyclodextrin complex and phospholipid component directly in water without foregoing dissolving into chlor
- Another object of this invention is a parenteral formulation based on a 2-hydroxypropyl cyclodextrin, preferably 2- hydroxypropyl ⁇ -cyclodextrin or 2-hydroxypropyl r-cyclodextrin, complex including an active drug substance selected from the group consisting of toremifene, desmethyl toremifene, tamoxifen and desmethyltamoxifen or a pharmaceutically acceptable non- toxic salt thereof, said complex being loaded into a liposome.
- the fully automated HPLC apparatus (Hewlett-Packard, USA) consisted of a pump 1090, an autosampler and autoinjector (79847A) with an injection volume of 10 ul and a fixed wavelength UV detector, 280 nm (79881A) .
- the chromatograms and peak areas were recorded with an integrator 3393.
- the separations were carried out at room temperature on a 35 * 4.6 mm stainless steel column (packed with 3-pm spherical octadecylsilanebonded silica particles; HS-3 C-18, (Perkin- Elmer, USA)
- the mobile phase consisted of a mixture of acetonitrile : 0.05 aqueous phosphate buffer containing 0.004 M of dimethyloctyl amine with a pH of 7.4.
- the flow rate was 0.8 ml/min.
- 2-hydroxypropyl- ⁇ -cyclodextrin (12 mg), POPC (32 mg), choleste ⁇ rol (4 mg), DMPG (dimyristoylphosphatidylglycerol) (8 mg) and toremifene citrate (2 mg) were dissolved in choloroform - met ⁇ hanol (2:1) and evaporated. The residue was dissolved in water and homogenized by sonication (Labsonic U, 50 W) . The stability of the solution was good; no turbidity was observed after one month in room temperature.
- cyclodextrin-free liposomes can be made by mixing the ingredients first in chloroform/ thanol (2:1) as described above for the cyclodextrin-containing liposomes.
- Emulsions prepared by dissolving the drug in a commercial fat emulsion are prepared by dissolving the drug in a commercial fat emulsion.
- Emulsan® 20 % manufactured by Emulsan
- Different amounts of toremifene citrate were dissolved in Emulsan solution and homogenized by sonication (Labsonic U, 50 W) .
- the toremifene concentrations were 10 mg/ml, 14 mg/ml and 20 mg/ml. After the homogenization the samples were filtered through the 0.2 ⁇ , 0.45 ⁇ m and 1.2 ⁇ m filters.
- the concentration of toremifene was determined from the filtrate with a spectrofotometric method using the wave length of 278 nm.
- the samples were dissolved in methanol and diluted in the concentration of 0.02 mg/ml.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69218241T DE69218241T2 (en) | 1991-12-10 | 1992-12-10 | MEDICINE FORMULATION FOR PARENTERAL USE |
US08/244,549 US5571534A (en) | 1991-12-10 | 1992-12-10 | Drug formulations for parenteral use |
JP51065093A JP3558344B2 (en) | 1991-12-10 | 1992-12-10 | Parenteral drug formulations |
CA002125408A CA2125408C (en) | 1991-12-10 | 1992-12-10 | Drug formulations for parenteral use |
AU31599/93A AU667861B2 (en) | 1991-12-10 | 1992-12-10 | Drug formulations for parenteral use |
EP93900114A EP0616529B1 (en) | 1991-12-10 | 1992-12-10 | Drug formulations for parenteral use |
NO942155A NO308578B1 (en) | 1991-12-10 | 1994-06-09 | Parenteral drug preparation |
FI942728A FI942728A0 (en) | 1991-12-10 | 1994-06-10 | Pharmaceutical compositions for parenteral use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919126209A GB9126209D0 (en) | 1991-12-10 | 1991-12-10 | Drug formulations for parenteral use |
GB9126209.7 | 1991-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993011757A1 true WO1993011757A1 (en) | 1993-06-24 |
Family
ID=10706001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FI1992/000339 WO1993011757A1 (en) | 1991-12-10 | 1992-12-10 | Drug formulations for parenteral use |
Country Status (11)
Country | Link |
---|---|
US (1) | US5571534A (en) |
EP (1) | EP0616529B1 (en) |
JP (1) | JP3558344B2 (en) |
AT (1) | ATE149828T1 (en) |
AU (1) | AU667861B2 (en) |
CA (1) | CA2125408C (en) |
DE (1) | DE69218241T2 (en) |
GB (1) | GB9126209D0 (en) |
NO (1) | NO308578B1 (en) |
WO (1) | WO1993011757A1 (en) |
ZA (1) | ZA929592B (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995015746A1 (en) * | 1993-12-10 | 1995-06-15 | The School Of Pharmacy | Liposome delivery systems |
WO1995033448A1 (en) * | 1994-06-03 | 1995-12-14 | The Secretary Of State For Defence | Stabilisation of photosensitive materials |
EP0695169A1 (en) * | 1993-04-22 | 1996-02-07 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
EP0893121A1 (en) * | 1997-06-27 | 1999-01-27 | Akzo Nobel N.V. | Oral liquid medicine solution |
US5929123A (en) * | 1996-05-02 | 1999-07-27 | Orion Corporation | Antioxidant compounds |
EP0931545A2 (en) * | 1997-11-26 | 1999-07-28 | Pfizer Products Inc. | Droloxifene pharmaceutical compositions |
WO2006001035A2 (en) * | 2004-06-28 | 2006-01-05 | Lifecare Innovations Pvt. Ltd. | Synergistic liposomal tamoxifen composition for topical application and method of preparing thereof. |
WO2007078060A1 (en) * | 2005-12-30 | 2007-07-12 | Amorepacific Corporation | Polymer-liposome nano-complexes and the preparation method thereof, and the composition of skin external application containing the same |
US9968583B2 (en) | 2009-03-30 | 2018-05-15 | Eisai R & D Management Co., Ltd. | Method of manufacture of liposome composition |
CN105748442B (en) * | 2016-04-07 | 2019-04-12 | 天津中医药大学 | A kind of preparation method of rhodioside and double load medicine anti-breast cancer nanometer formulations of tamoxifen |
US11071713B2 (en) | 2009-03-30 | 2021-07-27 | Eisai R&D Management Co., Ltd. | Liposome composition |
US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040186185A1 (en) * | 1998-05-07 | 2004-09-23 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
US6632447B1 (en) * | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US20030130316A1 (en) * | 2000-03-20 | 2003-07-10 | Steiner Mitchell S. | Method for chemoprevention of prostate cancer |
US6413533B1 (en) | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US6410043B1 (en) | 1998-05-07 | 2002-06-25 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US20040092602A1 (en) * | 1998-05-07 | 2004-05-13 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
YU68600A (en) * | 1998-05-07 | 2003-12-31 | The University Of Tennessee Research Corporation | Use of a chemopreventive agent in the manufacture of a pharmaceutical preparation for use in prevention of prostate cancerogenesis |
DE59903276D1 (en) * | 1998-12-04 | 2002-12-05 | Max Delbrueck Centrum | LIPOSOME-BASED TUMOR THERAPY THAT CONTAINS TAMOXIFEN |
FI109332B (en) | 1998-12-17 | 2002-07-15 | Orion Yhtymae Oyj | Soluble compositions of toremifene |
FI982733A (en) * | 1998-12-17 | 2000-06-18 | Orion Yhtymae Oyj | Soluble compositions of triphenylethylene estrogens |
US20040029831A1 (en) * | 2000-05-31 | 2004-02-12 | Kava Pharmaceuticals, Inc. | Extracts of kava-kava |
US6303157B1 (en) | 2000-05-31 | 2001-10-16 | Kava Pharmaceuticals, Inc. | Extracts of kava-kava |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
JP2005515988A (en) | 2001-11-29 | 2005-06-02 | ジーティーエックス・インコーポレイテッド | Prevention and treatment of androgen deficiency causing osteoporosis |
US20050239747A1 (en) * | 2004-04-21 | 2005-10-27 | Pharmaceutical Industry Technology And Development Center | Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods |
US20060019989A1 (en) * | 2004-07-21 | 2006-01-26 | Steiner Mitchell S | Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof |
US20160106717A1 (en) | 2004-09-24 | 2016-04-21 | Gen Pharma Holdings LLC | Cai-based systems and methods for the localized treatment of uveitis |
US20060116404A1 (en) * | 2004-09-24 | 2006-06-01 | Gary Robinson | CAI-based systems and methods for the localized treatment of ocular and other diseases |
WO2006052922A2 (en) * | 2004-11-08 | 2006-05-18 | Eastman Chemical Company | Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds |
WO2006052921A2 (en) * | 2004-11-08 | 2006-05-18 | Eastman Chemical Company | Cyclodextrin solubilizers for liquid and semi-solid formulations |
WO2006066074A2 (en) | 2004-12-16 | 2006-06-22 | The Regents Of The University Of California | Lung-targeted drugs |
US20060270641A1 (en) * | 2005-05-31 | 2006-11-30 | Steiner Mitchell S | Method for chemoprevention of prostate cancer |
US20070014845A1 (en) * | 2005-07-01 | 2007-01-18 | Yuanpeng Zhang | Liposomal delivery vehicle for hydrophobic drugs |
US8998881B2 (en) | 2005-08-10 | 2015-04-07 | Alza Corporation | Method for delivering drugs to tissue under microjet propulsion |
PL2076268T3 (en) | 2006-10-19 | 2013-06-28 | Genzyme Corp | Roscovitine for the treatment of certain cystic diseases |
PT2616078T (en) | 2010-09-16 | 2020-03-31 | Shimoda Biotech Pty Ltd | Fulvestrant compositions and methods of use |
WO2013008083A1 (en) | 2011-07-13 | 2013-01-17 | National Institute Of Pharmaceutical Education And Research (Niper) | Pharmaceutical composition for enhancing anticancer efficacy of tamoxifen |
EP2758052B9 (en) | 2011-09-18 | 2019-03-27 | Euro-Celtique S.A. | Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide |
TWI573792B (en) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | Novel therapeutic agents |
AU2014228321C1 (en) | 2013-03-15 | 2019-07-11 | The Regents Of The University Of California | Acyclic nucleoside phosphonate diesters |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
HRP20220651T1 (en) | 2014-09-15 | 2022-08-19 | The Regents Of The University Of California | Nucleotide analogs |
EP4327879A2 (en) | 2016-06-17 | 2024-02-28 | The Trustees of the University of Pennsylvania | Compounds, compositions and methods for prevention and/or treatment of cancer |
CA3040155C (en) | 2016-10-11 | 2024-01-16 | Euro-Celtique S.A. | Compound for use in the treatment of hodgkin lymphoma |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
FI3644999T3 (en) * | 2017-06-30 | 2023-03-19 | Celgene Corp | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
WO2019118855A1 (en) * | 2017-12-14 | 2019-06-20 | The Trustees Of The University Of Pennsylvania | Compounds and compositions for prevention and/or treatment of cancer |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2502951A1 (en) * | 1981-04-06 | 1982-10-08 | Sandoz Sa | TOPICAL PHARMACEUTICAL COMPOSITIONS IN THE FORM OF A MICRO-EMULSION |
DE3331459A1 (en) * | 1982-08-31 | 1984-03-01 | Martin Dr.med. 6900 Heidelberg Berger | Composition for tumour treatment containing diazoxide, and the use thereof |
EP0355604A2 (en) * | 1988-08-11 | 1990-02-28 | Lederle (Japan) Ltd. | Anti-cancer activity potentiator |
WO1990006106A1 (en) * | 1988-12-08 | 1990-06-14 | Patrinove | Hydrophilic composition of a lipophilic active principle, and liposome obtained with such composition |
WO1991017749A1 (en) * | 1990-05-17 | 1991-11-28 | Baylor College Of Medicine | Growth inhibitors and methods of treating cancer and cell proliferative diseases |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5793909A (en) * | 1980-12-03 | 1982-06-11 | Sankyo Co Ltd | Carcinostatic pharmaceutical having directivity to specific internal organ and its preparation |
FI67538C (en) * | 1982-05-27 | 1985-04-10 | Farmos Oy | PROCEDURE FOR FRAMSTATION OF AV (Z) -1,2-DIPHENYL-1- (4- (2- (N N-DIMETHYLAMINO) ETHOXY) PHENYL) -1-BUTEN |
EP0152379A3 (en) * | 1984-02-15 | 1986-10-29 | Ciba-Geigy Ag | Process for preparing pharmaceutical compositions containing unilamellar liposomes |
JPS60208910A (en) * | 1984-03-31 | 1985-10-21 | Green Cross Corp:The | Preparation of composite of hardly water-soluble drug and phospholipid |
GB8604528D0 (en) * | 1986-02-24 | 1986-04-03 | Ici Plc | Therapeutic agents |
IE62095B1 (en) * | 1988-03-29 | 1994-12-14 | Univ Florida | Pharmaceutical formulations for parenteral use |
DE3827974A1 (en) * | 1988-08-18 | 1990-02-22 | Boehringer Mannheim Gmbh | COMBINATION PREPARATIONS OF PROTEINKINASE-C INHIBITORS WITH LIPIDS, LIPID ANALOGS, CYTOSTATICA OR INHIBITORS OF PHOSPHOLIPASES |
MY106598A (en) * | 1988-08-31 | 1995-06-30 | Australian Commercial Res & Development Ltd | Compositions and methods for drug delivery and chromatography. |
DE3837596A1 (en) * | 1988-11-05 | 1990-05-10 | Rosink Gmbh & Co Kg | KANNENSTOCK |
-
1991
- 1991-12-10 GB GB919126209A patent/GB9126209D0/en active Pending
-
1992
- 1992-12-10 AT AT93900114T patent/ATE149828T1/en not_active IP Right Cessation
- 1992-12-10 US US08/244,549 patent/US5571534A/en not_active Expired - Lifetime
- 1992-12-10 AU AU31599/93A patent/AU667861B2/en not_active Ceased
- 1992-12-10 WO PCT/FI1992/000339 patent/WO1993011757A1/en active IP Right Grant
- 1992-12-10 EP EP93900114A patent/EP0616529B1/en not_active Expired - Lifetime
- 1992-12-10 JP JP51065093A patent/JP3558344B2/en not_active Expired - Lifetime
- 1992-12-10 ZA ZA929592A patent/ZA929592B/en unknown
- 1992-12-10 DE DE69218241T patent/DE69218241T2/en not_active Expired - Fee Related
- 1992-12-10 CA CA002125408A patent/CA2125408C/en not_active Expired - Lifetime
-
1994
- 1994-06-09 NO NO942155A patent/NO308578B1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2502951A1 (en) * | 1981-04-06 | 1982-10-08 | Sandoz Sa | TOPICAL PHARMACEUTICAL COMPOSITIONS IN THE FORM OF A MICRO-EMULSION |
DE3331459A1 (en) * | 1982-08-31 | 1984-03-01 | Martin Dr.med. 6900 Heidelberg Berger | Composition for tumour treatment containing diazoxide, and the use thereof |
EP0355604A2 (en) * | 1988-08-11 | 1990-02-28 | Lederle (Japan) Ltd. | Anti-cancer activity potentiator |
WO1990006106A1 (en) * | 1988-12-08 | 1990-06-14 | Patrinove | Hydrophilic composition of a lipophilic active principle, and liposome obtained with such composition |
WO1991017749A1 (en) * | 1990-05-17 | 1991-11-28 | Baylor College Of Medicine | Growth inhibitors and methods of treating cancer and cell proliferative diseases |
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, vol. 116, no. 16, 20 April 1992, Columbus, Ohio, US; abstract no. 158718p, T. LOFTSSON ET AL. 'solubilization and stabilization of drugs through cyclodextrin complexation' page 442 ;column 1 ; * |
FEBS LETTERS vol. 274, no. 1,2, November 1990, AMSTERDAM (NL) pages 107 - 110 H. WISEMAN ET AL. 'mechanism of inhibition of lipid peroxidation by tamoxifen and 4-hydroxytamoxifen introduced into liposomes' * |
JOURNAL OF CHROMATOGRAPHY, BIOMEDICAL APPLICATIONS vol. 414, no. 1, 20 February 1987, AMSTERDAM (NL) pages 192 - 196 R.D. ARMSTRONG ET AL. 'separation of tamoxifen geometric isomers and metabolites by bonded-phase beta-cyclodextrin chromatography' * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0695169A1 (en) * | 1993-04-22 | 1996-02-07 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
EP0695169A4 (en) * | 1993-04-22 | 1998-02-04 | Depotech Corp | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
WO1995015746A1 (en) * | 1993-12-10 | 1995-06-15 | The School Of Pharmacy | Liposome delivery systems |
WO1995033448A1 (en) * | 1994-06-03 | 1995-12-14 | The Secretary Of State For Defence | Stabilisation of photosensitive materials |
GB2302505B (en) * | 1994-06-03 | 1998-06-24 | Secr Defence | Stabilisation of photosensitive materials |
US5929123A (en) * | 1996-05-02 | 1999-07-27 | Orion Corporation | Antioxidant compounds |
US6204295B1 (en) | 1996-05-02 | 2001-03-20 | Orion Corporation | Antioxidant compounds |
US6127425A (en) * | 1997-06-27 | 2000-10-03 | Akzo Nobel N.V. | Oral liquid medicine solution |
EP0893121A1 (en) * | 1997-06-27 | 1999-01-27 | Akzo Nobel N.V. | Oral liquid medicine solution |
US6077871A (en) * | 1997-11-26 | 2000-06-20 | Pfizer Inc. | Droloxifene pharmaceutical compositions |
EP0931545A3 (en) * | 1997-11-26 | 2000-08-23 | Pfizer Products Inc. | Droloxifene pharmaceutical compositions |
EP0931545A2 (en) * | 1997-11-26 | 1999-07-28 | Pfizer Products Inc. | Droloxifene pharmaceutical compositions |
WO2006001035A2 (en) * | 2004-06-28 | 2006-01-05 | Lifecare Innovations Pvt. Ltd. | Synergistic liposomal tamoxifen composition for topical application and method of preparing thereof. |
WO2006001035A3 (en) * | 2004-06-28 | 2006-10-26 | Lifecare Innovations Pvt Ltd | Synergistic liposomal tamoxifen composition for topical application and method of preparing thereof. |
WO2007078060A1 (en) * | 2005-12-30 | 2007-07-12 | Amorepacific Corporation | Polymer-liposome nano-complexes and the preparation method thereof, and the composition of skin external application containing the same |
US9968583B2 (en) | 2009-03-30 | 2018-05-15 | Eisai R & D Management Co., Ltd. | Method of manufacture of liposome composition |
US11071713B2 (en) | 2009-03-30 | 2021-07-27 | Eisai R&D Management Co., Ltd. | Liposome composition |
CN105748442B (en) * | 2016-04-07 | 2019-04-12 | 天津中医药大学 | A kind of preparation method of rhodioside and double load medicine anti-breast cancer nanometer formulations of tamoxifen |
US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
Also Published As
Publication number | Publication date |
---|---|
NO942155D0 (en) | 1994-06-09 |
EP0616529A1 (en) | 1994-09-28 |
JPH07501813A (en) | 1995-02-23 |
DE69218241T2 (en) | 1997-06-19 |
JP3558344B2 (en) | 2004-08-25 |
NO942155L (en) | 1994-06-10 |
AU667861B2 (en) | 1996-04-18 |
AU3159993A (en) | 1993-07-19 |
GB9126209D0 (en) | 1992-02-12 |
ATE149828T1 (en) | 1997-03-15 |
CA2125408A1 (en) | 1993-06-23 |
EP0616529B1 (en) | 1997-03-12 |
ZA929592B (en) | 1993-08-06 |
CA2125408C (en) | 2004-04-20 |
DE69218241D1 (en) | 1997-04-17 |
US5571534A (en) | 1996-11-05 |
NO308578B1 (en) | 2000-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0616529B1 (en) | Drug formulations for parenteral use | |
US5407683A (en) | Pharmaceutical solutions and emulsions containing taxol | |
US6146659A (en) | Method of administering liposomal encapsulated taxane | |
US6461637B1 (en) | Method of administering liposomal encapsulated taxane | |
EP0843547B1 (en) | Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizers | |
EP2491919B1 (en) | Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof | |
KR20010031967A (en) | Pharmaceutical compositions containing cyclodextrins and taxoids | |
WO2002009667A2 (en) | Dispersions for formulating slightly or poorly soluble active ingredients | |
RU2391966C1 (en) | Based on botanical phospholipids nanosystem for actuation of biologically active compounds, and method of its manufacture (versions) | |
Zhao et al. | Solubilization of fluasterone | |
EP2349340A2 (en) | Stable aqueous formulations of water insoluble or poorly soluble drugs | |
JP2677576B2 (en) | Phospholipid transport vehicle for water-insoluble active ingredients | |
BRPI0619565A2 (en) | liposome compositions | |
CA2456970C (en) | Drug formulations for parenteral use | |
JP2758297B2 (en) | Liposome preparation | |
Jabbar | In-vitro; ex-vivo assessment of anti-inflammatory Tapentadol loaded non-ionic surfactant vesicular systems for effective transdermal delivery | |
JP5705978B2 (en) | Pharmaceutical composition of poorly soluble tricyclic derivatives with improved solubility | |
JP2005521712A (en) | Solubilization of weak bases | |
CN114558004B (en) | QTX125 pharmaceutical formulations | |
KR20080101056A (en) | Phospholipid nanospheres for solubilization of diterpenoid alkaloid and preparation | |
EP2654721B1 (en) | Pharmaceutical compositions of pyridinium and quinolinium derivatives | |
Jürgens et al. | A new formulation concept for drugs with poor water solubility for parenteral application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG CA CS FI HU JP KR NO NZ PL PT RO RU UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication | ||
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993900114 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2125408 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 942728 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08244549 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1993900114 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993900114 Country of ref document: EP |